Hematology - European Medical Journal

This site is intended for healthcare professionals

Continue

Hematology

Filter
13 Aug 2015

New therapeutic approaches for Hodgkin lymphoma

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton…
13 Aug 2015

Novel monoclonal antibody-based therapies for multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…
30 Jul 2015

Thrombosis in Haematological Disorders: Tailored Management Approaches

The meeting commenced with a talk from Prof Anna Falanga on the management of thrombosis in both onco-haematological and non-oncological diseases.
30 Jul 2015

Why Biosimilars Matter: An Innovative Solution to Improve Patient Access

The meeting was introduced by Prof Robin Foà who spoke about the difficulties for patients Prof Foà opened the symposium by highlighting…
30 Jul 2015

Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond

Prof Martin Dreyling opened the symposium by providing an overview of the current status of mantle cell lymphoma (MCL) and the current guidelines…
30 Jul 2015

Relapsed/Refractory Multiple Myeloma: The Current State of Play

Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions…
3 Jul 2015

SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma

An update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.
3 Jul 2015

Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL

At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the…
We’ve noticed you’re accessing
from North/South America.